The two drugs Velcade (bortezomib) and Revlimid (lenalidomide) are designed to treat the bone marrow cancer called multiple myeloma. A Phase I clinical trial has shown that the drugs may be more effective together than when used individually.

The trial was led by researchers at the Dana-Farber Cancer Institute in Boston. It included 38 patients who had their cancer recur despite other therapies. The patients were divided into groups that received successively higher doses of Velcade and Revlimid. Some patients also received the drug dexamethasone which can add to the anticancer effects of these two drugs.

Fifty-eight percent has responded to the combined treatment, six percent achieved complete remission. Researcher Dr. Paul Richardson said in a prepared statement "We are hopeful that this combination will prove to be a key therapeutic backbone in improving outcomes for our patients, both early and later in the course".

The treatment combination of Revlimid (lenalidomide), Oncovin (vincristine), Doxil (pegylated doxorubicin) and dexamethasone appears to be highly effective in multiple myeloma that has recurred or progressed following prior therapies.

According to an article published in the Annals of Oncology, researchers from the Cleveland Clinic conducted a clinical trial to evaluate this combination of drugs. The trial included 62 patients, 75 percent of the patients achieved an anticancer response and 29 percent of patients achieved a complete or near complete disappearance of detectable cancer.

The researchers note that determining treatment choices for those patients who recur after initial therapy is more challenging than treating patients that have not received prior therapy. Multiple myeloma is usually treated with chemotherapy -- however -- new treatments are evolving that are better tolerated, especially in older patients who cannot handle aggressive chemotherapy. The researchers continue to evaluate strategies in order to offer patients individualized treatment options.